Putting out the key findings in an article published recently in the Indian Journal of Medical Research - ‘Impact of telemedicine in STEMI care system: A five-year experience from Tamil Nadu ...

The medical records revealed that the patient was suffering from a massive heart attack, i.e. Acute Coronary Syndrome, Acute Inferior Wall Myocardial Infarction, which had to be managed with primary ...

than timely reperfusion treatment in patients with ST-segment elevation myocardial infarction (STEMI), regardless of the reperfusion strategy. Overall, 57% of patients had a normal LVEF ...

Objectives To evaluate emergency medical services (EMS) delays and their impact on time to treatment and mortality in patients with ST-elevation myocardial infarction (STEMI). Method We collected data ...

It's a common heart problem in newborn babies called Ventricular Septal Defect (VSD) that occurs when there is a gap between the heart's two lower chambers. It can make the heart do extra work and ...

Microvascular obstruction (MVO) is associated with heart failure (HF) following ST-segment–elevation myocardial infarction. Angiography-derived microcirculatory resistance (AMR), a wire- and adenosine ...

Right Ventricular Myocardial Infarction People who have a myocardial infarction (heart attack) caused by a blockage in the right coronary artery may suffer from damage to the right ventricular muscle, ...

ST Elevation Myocardial Infarction (STEMI) is one of the highest contributors to the same. The immediate 30-day period post-STEMI is critical in judging long-term patient outcomes. Thus, there is a ...

Other possible injuries that can occur along with nasal bone fractures include: Blockage of the tear duct Septal hematoma (blood collecting in the nasal cavity) Septal abscess (buildup of pus in the ...

Yet for thousands of families each year, this becomes reality when their child is diagnosed with an atrial septal defect (ASD) — a condition where a hole exists between the upper chambers of the ...

Angiopoietin-like 3 (ANGPTL-3) inhibition with the human monoclonal antibody, SHR-1918, reduces serum LDL-C by 22% to 30%, as well as triglyceride (TG) levels by 52% to 63%, in patients at moderate or ...